NASDAQ:VIR
Vir Biotechnology, Inc. Stock News
$9.73
-0.200 (-2.01%)
At Close: May 17, 2024
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
08:05pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
04:05pm, Tuesday, 06'th Sep 2022
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global He
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates
10:05pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
08:02pm, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates
07:33pm, Tuesday, 09'th Aug 2022
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc
Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates
10:15pm, Monday, 01'st Aug 2022 Zacks Investment Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Fast-Growing Stocks to Buy Now
01:00pm, Sunday, 31'st Jul 2022 The Motley Fool
ShockWave, Vir, and BioCryst are all seeing skyrocketing sales this quarter.
3 Fast-Growing Stocks to Buy Now
09:00am, Sunday, 31'st Jul 2022
ShockWave, Vir, and BioCryst are all seeing skyrocketing sales this quarter.
2 Biotech Stocks That Could Help Make You a Fortune
10:15am, Saturday, 30'th Jul 2022 The Motley Fool
These companies have seen triple-digit revenue growth in recent years.
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
02:03pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
04:47pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.
GSK Gears Up to Report Q2 Earnings: What's in the Cards?
02:59pm, Monday, 25'th Jul 2022 Zacks Investment Research
The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company report
3 Cheap Stocks To Buy Now
03:30pm, Tuesday, 12'th Jul 2022 The Motley Fool
COVID fighters and crypto brokers are super-cheap right now.
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
02:47pm, Monday, 27'th Jun 2022 Zacks Investment Research
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
